The global immunodiagnostics market size reached USD 20.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 35.3 Billion by 2033, exhibiting a growth rate (CAGR) of 6.5% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 20.0 Billion |
Market Forecast in 2033 | USD 35.3 Billion |
Market Growth Rate (2025-2033) | 6.5% |
Immunodiagnostics refers to an in-vitro diagnostic technology that uses antigen-antibody reaction for the detection of infectious and chronic diseases. It involves the use of radiological, fluorescent or color-forming enzymes and probes for the identification of antibodies that aid in enhancing the targeting range to identify disease progression. Immunodiagnostics also uses various reagents, instruments and software-based solutions for enzyme-linked immunosorbent assay, chemiluminescence, radioimmunoassay and rapid testing. These solutions are widely used for diagnosing diseases, such as cancer and autoimmune, respiratory, endocrine and oncological disorders, along with forensic psychology and environmental and food analysis. As a result, immunodiagnostics finds extensive applications across hospitals, clinical laboratories and research and academic institutes.
The increasing prevalence of chronic medical ailments and infections among the masses is one of the key factors driving the market growth. Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the growth of the market. There is also an escalating awareness among the consumers regarding the available treatment alternatives for ailments, such as hepatitis B, diabetes and cancer, which is positively impacting the demand for immunodiagnostics kits, assays and analyzers. Additionally, various technological advancements, such as the development of next-generation immunodiagnostics platforms, are anticipated to drive the market toward growth. These advanced point-of-care testing (POCT) systems offer enhanced diagnostic facilities for sepsis, acute cardiac infractions and other medical disorders with higher mortality rates. Other factors, including the increasing requirement for personalized medicines among the masses, along with extensive improvements in the healthcare infrastructure, especially in the developing economies, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global immunodiagnostics market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on product, technology, application and end user.
Breakup by Product:
Breakup by Technology:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arkray Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., F. Hoffmann-La Roche AG, Immunodiagnostic Systems Holdings PLC, Johnson & Johnson, Siemens AG, Sysmex Corporation and Thermo Fisher Scientific Inc.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Product, Technology, Application, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Abbott Laboratories, Arkray Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., F. Hoffmann-La Roche AG, Immunodiagnostic Systems Holdings PLC, Johnson & Johnson, Siemens AG, Sysmex Corporation and Thermo Fisher Scientific Inc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global immunodiagnostics market was valued at USD 20.0 Billion in 2024
We expect the global immunodiagnostics market to exhibit a CAGR of 6.5% during 2025-2033.
The increasing prevalence of chronic medical ailments, along with the rising demand for immunodiagnostics across clinical laboratories, hospitals, and research and academic institutes, owing to its accuracy, speed, and simplicity in providing results, is primarily driving the global immunodiagnostics market.
The sudden outbreak of the COVID-19 pandemic has led to the growing adoption of immunodiagnostics technology that uses antigen-antibody reaction for the detection of the coronavirus disease
Based on the application, the global immunodiagnostics market has been segregated into infectious diseases, oncology and endocrinology, hepatitis and retrovirus, bone and mineral, autoimmunity, cardiac biomarker, and others. Among these, infectious diseases currently hold the largest market share.
Based on the end user, the global immunodiagnostics market can be bifurcated into hospitals, clinical laboratories, academic and research centers, pharmaceutical and biotechnology industry, and others. Currently, hospitals exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global immunodiagnostics market include Abbott Laboratories, Arkray Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., F. Hoffmann-La Roche AG, Immunodiagnostic Systems Holdings PLC, Johnson & Johnson, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc.